Title:
Prevalence of Bacterial Urinary Tract Infections and Their Anti-microbial Susceptibility Test in a Tertiary Care Hospital in Bangladesh between April 2020 to April 2021

Authors:
Aklima Akter, Dr Md Arifur Rahman, Dr Farhana Khan, Dr Asma Akter Abbasy, Dr Farjana Sultana, Bangladesh

Abstract:

Urinary tract infection is the most common bacterial infection in Bangladesh and a common disease of women than men. An antimicrobial agent is used for the treatment of UTI. The increase in antibiotic resistance among uropathogens is a global problem. This study attempted to underline the prevalence of UTI patients affected by uropathogenic strains. The study was conducted among 3060 patients of different ages and sex from over a period of one year April 2020 to April 2021 through conventional cultural, biochemical methods as well as disk diffusion methods to determine the uropathogens and their antibiotic susceptibility pattern. Among 3060 samples, 1148 (37.5%) samples were found culture positive, 248 (22%) cases positive for male & 900 (78%) cases positive for females. Most of the UTI was caused by Escherichia coli 891 (60 %). Moreover Enterobacter spp (7.5%), Pseudomonas aeruginosa (11%), Proteus vulgaris (3.5%), Proteus mirabilis (2.5 %) Citrobacter freundii (1%), Klebsiella pneumoniae (3%), Staphylococcus spp (9.5%) Enterococcus faecalis (2%). 17 antibiotics were used against the isolated uropathogens. As it can be seen from (Table 2) Escherichia coli are sensitive to Meropenem 89%, Amikacin 80%, Gentamicin 74%, Nitrofuration 67%, Amoxiclave 71%, Ciprofloxacin 41%, Levofloxacin 37%, Doxycycline 40%. Pseudomonas aeruginosa sensitive to to Meropenem 72%, Amikacin 79%, Gentamicin 72%, Nitrofuration 54%, Amoxiclave 60%, Ciprofloxacine 43%, Levofloxacine 47%. Klebsiella Pneumoniae to Meropenem 82%, Amikacin 71%, Gentamicin 71%, Nitrofuration 50%, Amoxiclave 63%, Ciprofloxacin 32%, Levofloxacine 38%. Staphylococcus Spp Meropenem 83%, Amikacin 79%, Gentamicin 73%, Nitrofuration 60%, Amoxiclave 70%, Ciprofloxacine 46%, Levofloxacine 43%, Lenazolid 30%, Cotrimoxazole 43%. Proteus vulgaris Meropenem 84%, Amikacin 86%, Gentamicin 82%, Nitrofuration 56%, Amoxiclave 35%, Ciprofloxacine 28%, Levofloxacine 40%, Doxycycline 30%. Proteus mirabilis Meropenem 86%, Amikacin 84%, Gentamicin 84%, Nitrofuration 60%, Amoxiclave 63%, Ciprofloxacine 31%, Levofloxacine 43%, Doxycycline 30%. Enterobacter Spp Meropenem 78%, Amikacin 68%, Gentamicin 70%, Nitrofuration 47%, Amoxiclave 58%, Ciprofloxacin 38%, Levofloxacine 41%, Doxycycline 37%. Enterococcus faecalis Meropenem 80%, Amikacin 80%, Gentamicin 73%, Nitrofuration 59%, Amoxiclave 68%, Ciprofloxacine 30%, Levofloxacine 20%, Lenazolid 32%, Cotrimoxazole 43%. Citrobacter freundii Meropenem 88%, Amikacin 83%, Gentamicin 82%, Nitrofuration 60%, Amoxiclave 61%, Ciprofloxacin 33%, Levofloxacine 32%, Ceftriaxone 30%, Doxycycline 30%.

DOI: http://dx.doi.org/10.51505/ijmshr.2021.5609